Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ORMP logo ORMP
Upturn stock ratingUpturn stock rating
ORMP logo

Oramed Pharmaceuticals Inc (ORMP)

Upturn stock ratingUpturn stock rating
$2.27
Last Close (24-hour delay)
Profit since last BUY1.79%
upturn advisory
Consider higher Upturn Star rating
BUY since 9 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/17/2025: ORMP (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $3.25

1 Year Target Price $3.25

Analysts Price Target For last 52 week
$3.25 Target price
52w Low $1.82
Current$2.27
52w High $3.09

Analysis of Past Performance

Type Stock
Historic Profit 17.39%
Avg. Invested days 35
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/17/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 93.08M USD
Price to earnings Ratio -
1Y Target Price 3.25
Price to earnings Ratio -
1Y Target Price 3.25
Volume (30-day avg) 1
Beta 1.68
52 Weeks Range 1.82 - 3.09
Updated Date 09/17/2025
52 Weeks Range 1.82 - 3.09
Updated Date 09/17/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.61

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -683.65%

Management Effectiveness

Return on Assets (TTM) -4.94%
Return on Equity (TTM) -14.69%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -3129756
Price to Sales(TTM) 46.54
Enterprise Value -3129756
Price to Sales(TTM) 46.54
Enterprise Value to Revenue 2.86
Enterprise Value to EBITDA 0.52
Shares Outstanding 41003600
Shares Floating 32556858
Shares Outstanding 41003600
Shares Floating 32556858
Percent Insiders 13.16
Percent Institutions 17.77

ai summary icon Upturn AI SWOT

Oramed Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

Oramed Pharmaceuticals Inc. was founded in 2006 and is based in New York. The company focuses on the development of oral drug delivery systems. A key milestone is their focus on an oral insulin capsule for diabetes treatment. They have evolved into a clinical-stage pharmaceutical company.

business area logo Core Business Areas

  • Oral Insulin Development: Oramed is primarily focused on the development of an oral insulin capsule, ORMD-0801, as a potential treatment for diabetes. This is their lead product candidate.
  • Oral GLP-1 Development: Oramed also developing an oral GLP-1 (Glucagon-Like Peptide-1) candidate, ORMD-0802.

leadership logo Leadership and Structure

The leadership team includes Nadav Kidron (CEO). The company has a standard organizational structure with departments for research, development, clinical trials, and administration.

Top Products and Market Share

overview logo Key Offerings

  • ORMD-0801 (Oral Insulin Capsule): This is Oramed's lead product candidate, an oral insulin capsule being developed for the treatment of Type 2 diabetes and potentially for Type 1 diabetes. It is currently in Phase 3 clinical trials. Market share data is not yet available as the product is not yet commercially available. Competitors include Novo Nordisk (NVO), Eli Lilly (LLY), and Sanofi (SNY) which have injectable and other diabetes treatments. Success would disrupt the insulin delivery market.
  • ORMD-0802 (Oral GLP-1): This is Oramed's oral GLP-1 candidate, an oral GLP-1 under development for the treatment of Type 2 diabetes. It is currently in Phase 1 clinical trials. Market share data is not yet available as the product is not yet commercially available. Competitors include Novo Nordisk (NVO), Eli Lilly (LLY) which have injectable and other GLP-1 treatments. Success would disrupt the GLP-1 delivery market.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry, particularly the diabetes treatment market, is large and competitive. There is a growing demand for more convenient and effective diabetes management solutions. There is a large focus on GLP-1 agonists in the T2D market.

Positioning

Oramed is positioned as an innovative company aiming to disrupt the diabetes treatment market with its oral insulin and GLP-1 technology. Its competitive advantage lies in the potential convenience of oral delivery compared to injections.

Total Addressable Market (TAM)

The global diabetes market is estimated to be in the hundreds of billions of dollars. Oramed is positioned to capture a portion of this market if its oral insulin and GLP-1 therapies are successful.

Upturn SWOT Analysis

Strengths

  • Novel oral drug delivery technology
  • Potential to disrupt the diabetes treatment market
  • Strong intellectual property portfolio
  • Lead product candidate in Phase 3 trials

Weaknesses

  • Reliance on successful clinical trial outcomes
  • Limited commercialization experience
  • High cash burn rate
  • Small market capitalization

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • Positive clinical trial results
  • Growing demand for oral diabetes treatments

Threats

  • Failure of clinical trials
  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Patent infringement

Competitors and Market Share

competitor logo Key Competitors

  • Novo Nordisk (NVO)
  • Eli Lilly (LLY)
  • Sanofi (SNY)

Competitive Landscape

Oramed is a small player compared to established pharmaceutical giants. Its advantage lies in its potentially disruptive oral delivery technology. Oramed faces risks relating to competition.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by preclinical and clinical development milestones rather than revenue growth.

Future Projections: Future growth depends on the successful commercialization of ORMD-0801. Analyst projections vary based on the perceived likelihood of regulatory approval and market adoption.

Recent Initiatives: Recent initiatives include the progression of ORMD-0801 through Phase 3 clinical trials and securing funding for continued development.

Summary

Oramed Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing oral drug delivery systems, primarily for diabetes. While the company's novel approach presents a significant opportunity to disrupt the market, it faces numerous challenges including clinical trial risks, funding requirements, and competition from larger pharmaceutical companies. The success of its oral insulin and GLP-1 candidates is crucial for its future growth. Oramed's lack of market share compared to large companies is a significant issue it must consider.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated. Actual results may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Oramed Pharmaceuticals Inc

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 2006-04-21
President, CEO & Executive Chairman Mr. Nadav Kidron Esq.
Sector Healthcare
Industry Biotechnology
Full time employees -
Full time employees -

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.